{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:37:16Z","timestamp":1787063836929,"version":"build-2736575974"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aim\u2003Opsoclonus\u2013myoclonus\u2013ataxia syndrome (OMAS) is a rare autoimmune disorder. Approximately half of the cases are associated with neuroblastoma in children. This study's aim is to review management of our cases with OMAS-associated neuroblastoma for treatment approach as well as long-term follow-up.<\/jats:p>\n                  <jats:p>Methods\u2003Age at onset of symptoms and tumor diagnosis, tumor location, histopathology, stage, chemotherapy, OMAS protocol, surgery, and follow-up period were evaluated retrospectively in six patients between 2007 and 2022.<\/jats:p>\n                  <jats:p>Results\u2003Mean age of onset of OMAS findings was 13.5 months and mean age at tumor diagnosis was 15.1 months. Tumor was located at thorax in three patients and surrenal in others. Four patients underwent primary surgery. Histopathological diagnosis was ganglioneuroblastoma in three, neuroblastoma in two, and undifferentiated neuroblastoma in one. One patient was considered as stage 1 and rest of them as stage 2. Chemotherapy was provided in five cases. The OMAS protocol was applied to five patients. Our protocol is intravenous immunoglobulin (IVIG) 1 g\/kg\/d for 2 consecutive days once a month and dexamethasone for 5 days (20\u2009mg\/m2\/d for 1\u20132 days, 10\u2009mg\/m2\/d for 3\u20134 days, and 5\u2009mg\/m2\/d for the fifth day) once a month, alternatively by 2-week intervals. Patients were followed up for a mean of 8.1 years. Neuropsychiatric sequelae were detected in two patients.<\/jats:p>\n                  <jats:p>Conclusion\u2003In tumor-related cases, alternating use of corticosteroid and IVIG for suppression of autoimmunity as the OMAS protocol, total excision of the tumor as soon as possible, and chemotherapeutics in selected patients seem to be related to resolution of acute problems, long-term sequelae, and severity.<\/jats:p>","DOI":"10.1055\/s-0043-1768143","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T18:56:35Z","timestamp":1680720995000},"page":"057-062","source":"Crossref","is-referenced-by-count":3,"title":["Five Years Follow-up of Opsoclonus\u2013Myoclonus\u2013Ataxia Syndrome-Associated Neurogenic Tumors in Children"],"prefix":"10.1055","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6219","authenticated-orcid":false,"given":"Elif Habibe","family":"Aktekin","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u00d6zkan","family":"Gezer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lknur","family":"Erol","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Erbay","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faik","family":"Sar\u0131alio\u011flu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baskent University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00415-021-10536-3","article-title":"Opsoclonus-myoclonus-ataxia syndrome in children","volume":"269","author":"P Bhatia","year":"2022","journal-title":"J Neurol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00431-006-0247-4","article-title":"Long-term outcome of ten children with opsoclonus-myoclonus syndrome","volume":"166","author":"A Klein","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"e27776","DOI":"10.1002\/pbc.27776","article-title":"An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome","volume":"66","author":"C Wilbur","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2002.20.5.1209","article-title":"Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan","volume":"20","author":"K Yamamoto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study","volume":"36","author":"E Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"A Brunklaus","year":"2011","journal-title":"Pediatrics"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/medicina56080412","article-title":"The treatment of opsoclonus-myoclonus syndrome secondary to neuroblastic tumors-single centre experience and literature review","volume":"56","author":"A Mizia-Malarz","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial","volume":"2","author":"P A de Alarcon","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"228","author":"K K Matthay","year":"2005","journal-title":"Cancer Lett"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome","volume":"38","author":"M R Pranzatelli","year":"2016","journal-title":"Brain Dev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneuroim.2018.04.007","article-title":"Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS","volume":"321","author":"M R Pranzatelli","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"01","key":"ref12","first-page":"54","article-title":"Early detection and treatment of neuroblastic tumor with opsoclonus-myoclonus syndrome improve neurological outcome: a review of five cases at a single institution in Japan","volume":"26","author":"Y Takama","year":"2016","journal-title":"Eur J Pediatr Surg"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1212\/NXI.0000000000001153","article-title":"Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children","volume":"9","author":"T Rossor","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1817-1745.199462","article-title":"Neuroblastoma presenting as opsoclonus-myoclonus: a series of six cases and review of literature","volume":"11","author":"J P Meena","year":"2016","journal-title":"J Pediatr Neurosci"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosupression on developmental outcome of opsoclonus myoclonus syndrome","volume":"30","author":"W G Mitchell","year":"2015","journal-title":"J Child Neurol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00383-021-05014-w","article-title":"Surgical considerations for neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: a series of 14 patients from a single institution","volume":"38","author":"W R Johnston","year":"2022","journal-title":"Pediatr Surg Int"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/j.1442-200X.2012.03597.x","article-title":"Ganglioneuroblastoma, intermixed with opsoclonus-myoclonus syndrome","volume":"54","author":"H Kuyama","year":"2012","journal-title":"Pediatr Int"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00381-009-0979-3","article-title":"Neurological complications of neuroblastic tumors: experience of a single center","volume":"26","author":"G B Aydin","year":"2010","journal-title":"Childs Nerv Syst"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1097\/MPH.0000000000002131","article-title":"Neuroblastoma with opsoclonus-myoclonus-ataxia syndrome: role of chemotherapy in the management: experience from a tertiary care center in a resource-limited setting","volume":"43","author":"S Anand","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/practneurol-2011-000017","article-title":"The opsoclonus\u2013myoclonus syndrome","volume":"11","author":"J K Sahu","year":"2011","journal-title":"Pract Neurol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.21037\/tp-21-519","article-title":"Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome","volume":"11","author":"Q Sun","year":"2022","journal-title":"Transl Pediatr"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpn.2022.09.002","article-title":"Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome","volume":"41","author":"M Y\u0131ld\u0131r\u0131m","year":"2022","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1768143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:28:46Z","timestamp":1730798926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1768143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":22,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1768143","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}